Retatrutide's safety profile is based on Phase 2 clinical trial data. GI side effects are the most common, consistent with other GLP-1 receptor agonists, with generally manageable tolerability.
Medical Disclaimer: This page is for informational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before using any research chemical or peptide. Retatrutide is not FDA-approved for human use (unless noted).
Reported in approximately 45–65% of patients in Phase 2 trials, dose-dependent. Most pronounced during dose escalation.
Reported in approximately 20–30% of patients. Decreases with continued use.
Reported in approximately 20–25% of patients.
Reported in approximately 15–20% of patients.
Significant appetite suppression, consistent with triple agonist mechanism.
Rare but serious. Consistent with GLP-1 class effects.
Increased risk consistent with GLP-1 class and rapid weight loss.
Class warning based on rodent data, consistent with other GLP-1 receptor agonists.
Mean increase of approximately 4–5 bpm reported in Phase 2 trials.
Retatrutide should not be used in the following situations:
Based on Phase 2 trial data, nausea, vomiting, diarrhea, and constipation are the most common side effects. GI side effects are generally more pronounced than with semaglutide due to the triple agonist mechanism.
Retatrutide is not yet FDA-approved. Phase 2 data shows a manageable safety profile consistent with the GLP-1 drug class, but long-term safety data is not yet available.
Retatrutide appears to have higher rates of GI side effects compared to tirzepatide in clinical trials, potentially due to its additional glucagon receptor agonism. However, it also produces greater weight loss.
Phase 2 data suggests retatrutide may cause higher rates of nausea compared to semaglutide, particularly at higher doses. Slow dose escalation is important to manage GI tolerability.
Retatrutide is currently in Phase 3 clinical trials. Potential FDA approval could come in 2026–2027 if trials are successful.
Purgo Labs provides HPLC-verified, third-party tested Retatrutide for legitimate research purposes. Every batch includes a certificate of analysis.
Shop Retatrutide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.